Show simple item record

dc.contributor.authorRoy, P
dc.contributor.authorIslam, R
dc.contributor.authorSaha, D
dc.contributor.authorGogoi, M
dc.contributor.authorKumar, MD
dc.contributor.authorArora, N
dc.contributor.authorParihar, M
dc.contributor.authorKrishnan, Shekhar
dc.contributor.authorSaha, Vaskar
dc.date.accessioned2019-08-05T12:24:45Z
dc.date.available2019-08-05T12:24:45Z
dc.date.issued2019en
dc.identifier.citationRoy P, Islam R, Saha D, Gogoi M, Kumar Mishra D, Arora N, et al. Efficacy and safety of a bortezomib and reduced-intensity cytarabine-based protocol, TMC ALLR1, for relapsed childhood ALL in India. Br J Haematol. 2019 Jun 5.en
dc.identifier.pmid31168836en
dc.identifier.doi10.1111/bjh.16005en
dc.identifier.urihttp://hdl.handle.net/10541/621946
dc.description.abstractThe feasibility of bortezomib (BZB) in induction and reduced cytarabine doses in intensification was evaluated in children with relapsed acute lymphoblastic leukaemia (rALL) at a single centre in India. Of 55 children with rALL, 23 received supportive care and 7 refused treatment, with a median survival of 2 (interquartile range 1-6) months. Twenty-two (88%) of 25 children who were treated achieved second remission and 9 (69%) of 13 had end-of-induction minimal residual disease of <10-4 . The lower cytarabine dose was associated with decreased hospitalisation. One-year event-free and overall survival for the treated group was 74á7% (95% confidence interval 52-88) and 79á6% (58-91) respectively.en
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1111/bjh.16005en
dc.titleEfficacy and safety of a bortezomib and reduced-intensity cytarabine-based protocol, TMC ALLR1, for relapsed childhood ALL in Indiaen
dc.typeArticleen
dc.contributor.departmentDepartment of Paediatric Haematology Oncology, Tata Translational Cancer Research Centre, Tata Medical Centre, Kolkata, Indiaen
dc.identifier.journalBritish Journal of Haematologyen
dc.description.noteen]


This item appears in the following Collection(s)

Show simple item record